Psychological:

Business Communications Company Inc.
Management Report  September 2005


Table of Contents

Introduction

The emotional and behavioral disorder drug market is changing as a result of the heightened awareness of these diseases in young children and adolescents and the use of drugs dedicated to controlling these problems. The key objective now is safe use and correct diagnosis. The drugs previously used had many side effects, the principal one being suicidal tendencies. Now the market is moving towards drugs that are safer to use. However, much remains to be done.

Many companies are doing research on drugs with fewer side effects and by the end of the decade, it is expected that more of them will be on the market. Efforts are underway to perform clinical trials to prove the safety of these drugs for children. These currently still are considered as “off label” uses.

Available alternatives and preferences for various drugs have made the industry acutely aware of related issues and economic characteristics. This timely BCC study looks at almost all the drug markets affected by these factors. It discusses the strengths and weaknesses of drugs being used for children, and whose safety still has not been established by regulatory authorities. Also examined are the demographics of drug use as divided by preschoolers and other age groups. In addition, the report looks at worldwide sales by region.

SCOPE OF STUDY

The report contains:

• An overview of the behavioral and emotional disorders in children and adolescents
• Sales figures for the following categories of drugs: benzodiazepines, mood stabilizers, antipsychotics, SSRIs, tricyclic antidepressants, CNS stimulants and nonstimulants
• Market projections on their worldwide use to 2010
• Drug categorizations by disorder with sales figures for each
• Profiles of the companies selling these products
• Discussion of factors affecting markets as a result of regulatory issues.

REPORT HIGHLIGHTS

The world market for drugs to treat mental, emotional and behavioral problems in children and adolescents is estimated at $13.4 billion in 2005 and is expected to rise at an average annual growth rate (AAGR) of 7.2% to $19 billion in 2010.

Antianxiety drugs and antidepressants currently represent the largest market, but will rise at an AAGR of only 5.5% through the period.

Drugs for bipolar, autistic, eating disorders and schizophrenia will fare somewhat better, rising at an AAGR of 5.8% to $4.1 billion in 2010.

The category that includes ADHD and conduct and learning disorders will rise the fastest at an AAGR of 9.7% to become the largest segment in 2010 at $8.1 billion.

For full details, please email jenniferc@cmsinfo.com

Order Form

For more information about us, visit CMSinfo.